High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Shares in Wegovy maker Novo Nordisk surged this morning after it reported strong demand for its new weight-loss pill and upgraded its guidance. The Danish drugmaker said total prescriptions for the Wegovy pill reached around 1.
May 6 (Reuters) - European shares rose on Tuesday, with oil prices dropping and investor optimism rising after U.S.
Total prescriptions for the Wegovy pill reached around 1.3 million in the first quarter and have exceeded 2 million since it launched.
COPENHAGEN, May 6 () - Novo Nordisk, the maker of weight-loss drug Wegovy, on Wednesday reported first-quarter revenue and adjusted operating profit above expectations and said its outlook for the year was slightly improved. The Danish drugmaker is banking on demand for its new weight-loss pill as competition with U.
VTRS gears up to report Q1 results as import alerts, regional pressures and growth in key brands shape expectations ahead of May 7 release.
Lilly's Foundayo is off to a strong start, drawing new prescribers and patients as broad pharmacy access and payer coverage fuel early oral obesity momentum.
Eli Lilly (NYSE:LLY) received another bullish call from Wall Street. Barclays analyst Emily Field raised her price target on Eli Lilly stock to $1,400 from $1,350 and reiterated an Overweight rating, citing tirzepatide momentum that “takes focus back to the big picture.” The firm also lifted its estimates following the company’s Q1 2026 report. For ... Barclays Hikes Eli Lilly Price Target to $1,400: Tirzepatide Momentum Steals the Show
Competition from Eli Lilly puts pressure on margins despite strong early uptake
Novo Nordisk A/S (NYSE:NVO) is experiencing strong early uptake for its new weight-loss pill, but intensifying competition with U. S.
Novo Nordisk's oral semaglutide for obesity is gaining traction as demand picks up for the new pill version of Ozempic. The FDA has proposed restricting compounding of GLP-1 drugs such as semaglutide, which could support branded products. Rival Eli Lilly is facing delays to its own obesity pill, giving Novo Nordisk more room to build its lead in oral GLP-1 therapies. Novo Nordisk is responding with new leadership, pricing changes, and cost reductions to sharpen its obesity drug focus. Novo...
NVO heads into Q1 with strong GLP-1 drug demand and new Wegovy pill rollout, but pricing pressure, weak guidance and Eli Lilly rivalry weigh on outlook.
CPRX's Q1 earnings are expected to beat estimates on strong Firdapse demand and rising Agamree sales, while Fycompa faces patent-driven pressure.
Guggenheim trimmed its price target (PT) on Amgen (NASDAQ:AMGN) to $340 from $351 on Monday, May 4, while maintaining a Neutral rating. The revision follows the biotech’s Q1 2026 earnings release and reflects a model update rather than a wholesale thesis change. Amgen stock recently slipped, trading at $324 as of Monday after closing at ... Guggenheim Trims Amgen Price Target to $340: Is the Biotech Giant Losing Its Edge?
The Food and Drug Administration has recorded two ‘serious’ cases in patients taking Eli Lilly’s weight-loss pill.
Investing.com -- Eli Lilly and Company (NYSE:LLY) fell 3% Monday, while Novo Nordisk (NYSE:NVO) rose 2% after Evercore ISI analyst Umer Raffat flagged a liver case in the FDA adverse event database that has "potential to create confusion" for Eli Lilly.
Ozempic oral pill will be produced entirely in the US and distributed through more than 70,000 pharmacies in the US.
Novo Nordisk (NYSE:NVO) is exploring semaglutide as a potential treatment for alcohol use disorder, expanding beyond its current uses in diabetes and obesity. The company has also begun Phase 1 trials for LX9851, an oral obesity and metabolic disorder drug developed with Lexicon Pharmaceuticals. These moves highlight ongoing clinical work in metabolic and related conditions, with implications for future treatment options. Novo Nordisk is currently trading at $43.88, with the share price up...
Is NVO a good stock to buy? We came across a bullish thesis on Novo Nordisk A/S on Unfair Advantage’s Substack by AK. In this article, we will summarize the bulls’ thesis on NVO. Novo Nordisk A/S’s share was trading at $38.52 as of April 23rd. NVO’s trailing and forward P/E were 10.65 and 11.38 respectively according […]
ON Semiconductor, Pfizer, Uber, McDonald’s, and many more will report earnings this week. Economic releases will include the April jobs report and purchasing managers index.
Shares of healthcare tech company GoodRx (NASDAQ:GDRX) jumped 9.5% in the afternoon session after it announced it would provide access to Novo Nordisk's oral semaglutide medication, known as the Ozempic pill, for eligible self-pay patients with type 2 diabetes.
Eli Lilly and Company (NYSE:LLY) was among the stocks Jim Cramer highlighted, as he discussed the massive AI infrastructure buildout. Cramer noted that the company is “creating a lot of jobs,” as he said: Okay, then there’s one that’s totally away from manufacturing or industry or tech, and that’s Eli Lilly. It was up 10%. […]
Novo Nordisk (CPSE:NOVO B) is rolling out its oral Ozempic (semaglutide) tablet across the US as the only FDA approved oral GLP-1 for adults with type 2 diabetes. The company plans broad distribution through more than 70,000 US pharmacies. New access partnerships with WW International and GoodRx aim to support patients through digital health tools, discounts and self pay options. The launch includes a mix of insurance coverage pathways and cash pay programs targeting both insured and self...
The prescription data collected for Eli Lilly's new weight-loss pill, Foundayo, is flawed, analysts said Friday.
Oral version targets broader access as GLP-1 demand grows
Novo will sell 1.5 mg, 4 mg and 9 mg Ozempic pills as it rebrands Rybelsus in the US.
Oral version expands access to diabetes therapy
European equities traded in the US as American depositary receipts were trending marginally higher l
Beneath Eli Lilly's (LLY) headline numbers lies a structural business model shift that the broader market seems to currently undervalue, driven in part by a recent valuation penalty following Novo Nordisk's faster initial prescription ramp for its oral therapy. While early volume data favors the competitor’s established brand capture, the central equity debate remains focused on the friction between high demand and pricing pressure from pharmacy benefit managers. Critics highlight dropping reali
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
